Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals. While there is strong growth potential in the reagent business and a strategic focus on innovation, the financial performance is concerning with a net loss and declining EBITDA. The Q&A highlights positive trends in Asia Pacific and biopharma, but challenges in EMEA and U.S. academic sectors persist. The cautious guidance for 2025 and stable U.S. performance balance the negatives, leading to a neutral sentiment rating.
The earnings call reveals mixed signals. While there are positive aspects such as improved net loss, increased service revenue, and strategic product launches, there are concerns about declining revenue, lower gross margins, and uncertainties in academic funding. The Q&A highlights management's cautious optimism, with no clear guidance on macroeconomic impacts. Despite some positive product developments, the overall sentiment remains neutral due to the lack of strong financial performance and clear guidance. The market's reaction is likely to be muted, resulting in a neutral stock price movement.
The earnings call reveals several negative indicators: declining revenue, gross margins, and increased operating losses. Despite some positive elements like service revenue growth and share repurchases, the overall financial performance is weak. The Q&A highlights uncertainties regarding tariffs and funding, and management's unclear responses further exacerbate concerns. The revised revenue outlook and increased losses suggest potential growth challenges. Combined, these factors indicate a likely negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.